Friday, August 28, 2026

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven capital allocation.

UWMC $2B

Yet Another Value Podcast Aug 27 13 clicks

Aug 20 ELALF $3.2B

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

Yet Another Value Podcast 12 clicks

Aug 20 CCC $3.9B

CCC Is in the Middle of the Wreckage

scuttleblurb 17 clicks

From X

@natstewart5 Aug 5 1 click

Nat Stewart on X

@JohnHuber72 I believe $NRP's production jump in Appalachia was primary due to $ARLP's Tunnel Ridge mine, which should be a stable producer going forward.

@RagingVentures Aug 4

Raging Capital Ventures on X

Bought $CTRI ~$22-$22.50 into this post-earnings sell off. Margins were disappointing, but $CTRI is growing nicely given the tailwinds in energy and utility services. Margins should follow in time from greater scale & pricing power, and the balance sheet is vastly improved.

@RagingVentures Aug 1

Raging Capital Ventures on X

Any fundamental views on $RH here? I’ve been recently trying on the short as a trade into the $180 level with some success, feels like it has squeezed higher due to de-grossing/de-leveraging. Other building names are very weak with 10-year testing 5%.

@RagingVentures Aug 1 1 click

Raging Capital Ventures on X

Sold my $BILL on this 50%+ run off the lows, and continue to actively trade around core $HUBS and $WDAY positions by regularly writing calls or shorting puts (and sometimes boxing my longs). The volatility has been insane. Sold $ESTC for now. Also, I’m now short a small amount of $ADBE, $NOW, $TEAM, $CXM and $YEXT into July’s de-grossing/de-leveraging squeeze.

@mavix_leon Jul 31 3 clicks

mavix on X

Portfolio July 2026: Toyokumo $4058 Evolution $EVO Centrotec $CEV.HM Leatt $LEAT BioRem $BRM.V Secunet Security Networks $YSN -undisclosed- Shelly Group $SLYG Enogia $ALENO.PA Lindbergh $LDB.MI ErreDue $RDUE -undisclosed- Circle Group $CIRC.MI -undisclosed- https://t.co/GRWGeOhgeH https://t.co/3qWfVW1705

@mavix_leon Jul 31 2 clicks

mavix on X

I just published my Portfolio Update for July '26. It includes: ▫️My current Portfolio & position sizes ▫️Earnings Update about $EVO, $BRM.V, $ALENO.PA, -undisclosed- ▫️Recent news & information about $LEAT, $CIRC.MI, $SLYG, $4058, $EVO Link for the blog in Bio 😊 https://t.co/7eVa84MGbr

@cfrischer1 Jul 29

Charles Frischer on X

$NN I agree with those who say I have been overly optimistic on timing. That said, I have underestimated the value of the NN low band spectrum. This article gives a good idea about potential demand for low band from Elon and SpaceX.

@cfrischer1 Jul 29

Charles Frischer on X

$NN Given demand from direct to device carriers, we might receive bids from 4 or 5 parties willing to pay a fair price for the NN low band spectrum. These bidders could include big three, Amazon and SpaceX.

SA 2026-08-20

Seabridge Gold: Fairly Valued Now But Big Upside

Seabridge Gold's KSM gold-copper project could re-rate on a joint venture, 2027 feasibility study and infrastructure progress, with gold…

SA $3.3B

Redfern Research Aug 20

$DNOW: the boring distributor that could double on 2029 numbers | Firebird Management

DNOW’s MRC Global merger targets $75 million of synergies, with a 2029 bull case of $30 to $32 per share driven by cash flow and rerating.

DNOW $2.8B

Yet Another Value Podcast Aug 14 9 clicks

$UWMC lost $600m hedging a deal they'd already lost

UWMC booked a roughly $600 million Q2 hedging loss tied to TWO months after the deal collapsed, contributing to an expensive capital raise.

UWMC $2B

Yet Another Value Blog Aug 11 11 clicks

$CBZ: stop the buybacks and restart the M&A flywheel? | Reference Equity

CBIZ activist Ryan Bunn urges ending buybacks, issuing equity and resuming bolt-on acquisitions to delever after the $2.3 billion Marcum…

CBZ $3B

Yet Another Value Podcast Jul 14 2 clicks

$VEON: a busted EM telecom hiding a 4x? | Samit Umatiya, UIG Funds

VEON’s 84% Kyivstar stake and JazzCash underpin a sum-of-the-parts case for 4x upside, despite its sanctioned shareholder, capital…

VEON $4.8B

Yet Another Value Blog Jul 1 1 click

Under The Hood, Wingstop Inc. ($WING)

Wingstop generates most of its $697 million revenue from franchise royalties across a 3,153-restaurant, 98%-franchised system while…

WING $2.8B

Bearhold Research Jun 28 2 clicks

A Hardware Multiple on a Software Powerhouse

A software powerhouse posts a record quarter while trading at a 52-week low, raising a valuation disconnect between its business model and…

CALX $2.2B

The Value Road Jun 12 5 clicks

Vidrala

Vidrala has grown from a Spanish glass-container maker into a multi-country packaging platform with expanding Latin American exposure.

VDRFF $3.6B

smallvalue. May 19 6 clicks

AXT’s Tongmei Problem: Great Asset, Fragile Economics

AXT’s 85.5%-owned Tongmei depends on offshore pricing, export approvals and transfer-pricing economics despite AI-optics demand.

AXTI $4.2B

Maius Partners Apr 2 7 clicks

Shift4 Company Podcast Episode Released!

Shift4 built its payments business by acquiring gateway nodes and migrating merchants to its processing platform; revenue has compounded…

FOUR $3.3B

Speedwell Memos Feb 19 1 click

HWKN · short

Hawkins INC

Hawkins (HWKN) faces margin pressure as cost increases and municipal budget constraints weigh on its water-chemical distribution business.

HWKN $2.6B

Value Investors Club May 30 1 click

BHVN 2026-08-27

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Biohaven’s $795 million global opakalim licensing deal with SK Biopharmaceuticals boosts cash, lowers R&D spending and extends its funding…

BHVN $2.1B

Edmund Ingham Aug 27 1 click

My Biggest Position: A Monopoly Priced for Failure

A former value-investor darling, down 50%, pairs a monopoly with a recurring-revenue razor-and-blade business; debt paydown, margin…

PBI $2.4B

Treasure Hunting Feb 5 3 clicks

Haw Par Corporation Limited

Haw Par combines Tiger Balm’s stable cash flows with property, leisure and healthcare operations plus stakes in UOB and UOL.

HAWPY $3B

smallvalue. Dec 17 4 clicks

National Beverage Update

National Beverage’s rare share repurchase is framed as a buy signal, with 50% upside projected.

FIZZ $3B

Nat Stewart - Stock Picking Newsletter Nov 25 3 clicks

Tis The (Earnings) Season

Argentine banks, tariff-exposed stocks and Customer’s Bancorp anchor an earnings-season watchlist after Milei’s election victory,…

CUBI $2.7B

Cluseau Research Oct 27 3 clicks

When extend and pretend is a virtue

Upstart says longer repayment terms lifted Q1 debt-settlement acceptances 50%, but does not disclose delinquency changes or the number of…

UPST $2.4B

John Hempton's Newsletter May 6 2 clicks

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B

John Hempton's Newsletter Oct 31 1 click

Late August 2026 Random Ramblings

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

CCC Is in the Middle of the Wreckage

From X

Nat Stewart on X

Raging Capital Ventures on X

Raging Capital Ventures on X

Raging Capital Ventures on X

mavix on X

mavix on X

Charles Frischer on X

Charles Frischer on X

Investor Letters

Seabridge Gold: Fairly Valued Now But Big Upside

$DNOW: the boring distributor that could double on 2029 numbers | Firebird Management

$UWMC lost $600m hedging a deal they'd already lost

$CBZ: stop the buybacks and restart the M&A flywheel? | Reference Equity

$VEON: a busted EM telecom hiding a 4x? | Samit Umatiya, UIG Funds

Under The Hood, Wingstop Inc. ($WING)

A Hardware Multiple on a Software Powerhouse

Vidrala

AXT’s Tongmei Problem: Great Asset, Fragile Economics

Shift4 Company Podcast Episode Released!

Hawkins INC

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

My Biggest Position: A Monopoly Priced for Failure

Haw Par Corporation Limited

National Beverage Update

Tis The (Earnings) Season

When extend and pretend is a virtue

Sarepta Risk and the FDA

Publications we follow

YouTube 4

Blogs 12

Seeking Alpha 29 of 159

X accounts we follow

Investor letters we follow

Sectors

Friday, August 28, 2026

Nat Stewart on X

Raging Capital Ventures on X

Raging Capital Ventures on X

Raging Capital Ventures on X

mavix on X

mavix on X

Charles Frischer on X

Charles Frischer on X

Investor Letters

Publications we follow

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 29 of 159

X accounts we follow

Investor letters we follow

Sectors